Background: Preliminary studies have shown that patients with essential hypertension and
left ventricular hypertrophy have an excess of circulating insulin-like growth factor-1 (IGF-1) …

In a previous work we have found than an association exists between the presence of left
ventricular hypertrophy (LVH) and increased circulating levels of insulin-like growth factor I …

There is some evidence that cardiac rather than circulating insulin-like growth factor-1 (IGF-
1) levels contribute to the development of renovascular hypertensive left ventricular …

Objectives Growth hormone (GH) and insulin-like growth factor-1 (IGF-1) interfere with
cardiac mass (left ventricular mass; LVM) development. We investigated the role of the …

Several trials have suggested that insulin-like growth factor-1 (IGF-1) may have a
pathophysiological role in the development of arterial essential hypertension. To verify the …

OBJECTIVE: This study was undertaken to compare the effects of valsartan with those of
enalapril on regression of left ventricular hypertrophy in patients with mild to moderate …

Angiotensin II influences development of left ventricular hypertrophy (LVH) by stimulating
cardiomyocyte hypertrophy, fibroblast proliferation, and collagen synthesis. Because pro …

Regression of Left Ventricular Mass with Captopril and Metoprolol, and the Effects on
Glucose and Lipid Metabolism Page 1 Regression of Left Ventricular Mass with Captopril …

Hemodynamic and non-hemodynamic factors contribute to the development of left
ventricular hypertrophy (LVH). The presence of LVH is an important independent risk factor …

Angiotensin II (AII) is known to be a growth stimulating factor for myocardial cells. We
examined whether an exaggerated responsiveness to AII might aggravate left ventricular …